NASDAQ:DRMA Dermata Therapeutics (DRMA) Stock Price, News & Analysis $5.74 +0.39 (+7.29%) Closing price 08/29/2025 03:59 PM EasternExtended Trading$5.63 -0.11 (-1.92%) As of 08/29/2025 04:42 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Dermata Therapeutics Stock (NASDAQ:DRMA) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Dermata Therapeutics alerts:Sign Up Key Stats Today's Range$5.14▼$5.7450-Day Range$5.33▼$7.3052-Week Range$5.09▼$24.90Volume27,008 shsAverage Volume29,660 shsMarket Capitalization$3.91 millionP/E RatioN/ADividend YieldN/APrice Target$10.00Consensus RatingBuy Company Overview Dermata Therapeutics, Inc., a late-stage medical dermatology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions and diseases. The company's lead product candidate is DMT310, which has completed Phase IIb clinical trial for treatment of moderate-to-severe acne; and Phase Ib proof of concept (POC) trial for Mild-to-Moderate Psoriasis, as well as is in a Phase 2 clinical trial for treatment of moderate-to-severe rosacea. It is also developing DMT410 that has completed Phase Ib POC trials for the treatment of anxillary hyperhidrosis and aesthetic conditions. Dermata Therapeutics, Inc. was incorporated in 2014 and is headquartered in San Diego, California. Read More Dermata Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks60th Percentile Overall ScoreDRMA MarketRank™: Dermata Therapeutics scored higher than 60% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingDermata Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageDermata Therapeutics has only been the subject of 1 research reports in the past 90 days.Read more about Dermata Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Dermata Therapeutics is -0.35, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Dermata Therapeutics is -0.35, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioDermata Therapeutics has a P/B Ratio of 0.70. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.78% of the float of Dermata Therapeutics has been sold short.Short Interest Ratio / Days to CoverDermata Therapeutics has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Dermata Therapeutics has recently decreased by 96.13%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldDermata Therapeutics does not currently pay a dividend.Dividend GrowthDermata Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted0.78% of the float of Dermata Therapeutics has been sold short.Short Interest Ratio / Days to CoverDermata Therapeutics has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Dermata Therapeutics has recently decreased by 96.13%, indicating that investor sentiment is improving significantly. News and Social Media2.5 / 5News Sentiment0.49 News SentimentDermata Therapeutics has a news sentiment score of 0.49. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 1.05 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Dermata Therapeutics this week, compared to 0 articles on an average week.Search Interest5 people have searched for DRMA on MarketBeat in the last 30 days. This is an increase of 400% compared to the previous 30 days. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Dermata Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders18.50% of the stock of Dermata Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 8.67% of the stock of Dermata Therapeutics is held by institutions.Read more about Dermata Therapeutics' insider trading history. Receive DRMA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Dermata Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. DRMA Stock News HeadlinesDermata Therapeutics (NASDAQ:DRMA) Shares Up 0.9% - Should You Buy?August 29 at 3:21 AM | americanbankingnews.comDermata Therapeutics Regains Nasdaq Compliance by August 2025August 26, 2025 | msn.comThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, and he's been proven right time and time again. And now, while the media focuses on Tesla's "demise," he's uncovered an AI breakthrough that's about to make Elon's doubters eat their words yet again. According to his research, if you listen to the media and miss out on Elon's newest breakthrough, it's going to cost you the fortune of a lifetime. | Brownstone Research (Ad)Maxim Group Cuts Dermata Therapeutics (NASDAQ:DRMA) Price Target to $10.00August 24, 2025 | americanbankingnews.comDermata Therapeutics Reports Positive Phase 3 Trial ResultsAugust 13, 2025 | msn.comDermata Therapeutics, Inc. Common Stock (DRMA) - NasdaqAugust 9, 2025 | nasdaq.comDermata Therapeutics, Inc. (DRMA) - Yahoo FinanceJuly 11, 2025 | finance.yahoo.comDermata Therapeutics Inc News (DRMA) - Investing.comJuly 10, 2025 | investing.comSee More Headlines DRMA Stock Analysis - Frequently Asked Questions How have DRMA shares performed this year? Dermata Therapeutics' stock was trading at $13.50 at the beginning of the year. Since then, DRMA shares have decreased by 57.5% and is now trading at $5.74. How were Dermata Therapeutics' earnings last quarter? Dermata Therapeutics, Inc. (NASDAQ:DRMA) announced its earnings results on Wednesday, August, 13th. The company reported ($1.66) earnings per share for the quarter, topping analysts' consensus estimates of ($2.90) by $1.24. When did Dermata Therapeutics' stock split? Dermata Therapeutics's stock reverse split on the morning of Thursday, May 16th 2024.The 1-15 reverse split was announced on Thursday, May 16th 2024. The number of shares owned by shareholders was adjusted after the market closes on Thursday, May 16th 2024. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split. When did Dermata Therapeutics IPO? Dermata Therapeutics (DRMA) raised $18 million in an initial public offering (IPO) on Friday, August 13th 2021. The company issued 2,571,428 shares at a price of $7.00 per share. Who are Dermata Therapeutics' major shareholders? Top institutional shareholders of Dermata Therapeutics include Armistice Capital LLC (50.50%). How do I buy shares of Dermata Therapeutics? Shares of DRMA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Dermata Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Dermata Therapeutics investors own include BIOLASE (BIOL), CNS Pharmaceuticals (CNSP), Esports Entertainment Group (GMBL), Jiuzi (JZXN), Kiora Pharmaceuticals (KPRX), ENDRA Life Sciences (NDRA) and Sonnet BioTherapeutics (SONN). Company Calendar Last Earnings8/13/2025Today8/30/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:DRMA CIK1853816 Webwww.dermatarx.com Phone858-800-2543FaxN/AEmployees8Year FoundedN/APrice Target and Rating Average Price Target for Dermata Therapeutics$10.00 High Price Target$10.00 Low Price Target$10.00 Potential Upside/Downside+74.2%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Trailing Twelve Months)($16.41) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$12.29 million Net MarginsN/A Pretax MarginN/A Return on Equity-214.98% Return on Assets-153.76% Debt Debt-to-Equity RatioN/A Current Ratio6.47 Quick Ratio6.47 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$8.24 per share Price / Book0.70Miscellaneous Outstanding Shares682,000Free Float556,000Market Cap$3.91 million OptionableNot Optionable Beta0.56 Social Links The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free Report This page (NASDAQ:DRMA) was last updated on 8/30/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredBuffett to put 90% of his money in this one stock?CPA and CFA says you have WAY too many stocks - just buy these 3 After years working at the biggest accoun...Altimetry | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredTrump’s national nightmare is hereAI is no longer just about chatbots — it’s becoming the backbone of the global economy. While U.S. firms push ...Porter & Company | Sponsored“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | SponsoredNew law could create $3.7 trillion tsunami.During a meeting in Washington D.C., Jeff Brown discovered a bold initiative. He calls it “President Trump’...Brownstone Research | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Dermata Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Dermata Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.